Early Anti-TNF Therapy Helps Reduce Health Care Utilization in Crohn Disease
Researchers compared the difference in overall health care utilization in patients with IBD who started anti-TNF therapy 2 years vs more than 2 years postdiagnosis.
Diagnosis & Disease Information
Increased Processed Meat Consumption Associated With Mortality Risk Among Patients With IBD
Investigators assessed the association between processed meat consumption and risk for mortality among patients with inflammatory bowel disease.
Ustekinumab Efficacy in a Real-World Setting of Patients With Difficult-to-Treat Crohn Disease
Investigators assessed the efficacy and clinical effects of ustekinumab in patients with Crohn disease who had a previously failed anti-TNF therapy attempt.
IBD and Obesity: Is There a Connection?
One key factor that has developed increasing research interest is the role of a patient’s BMI, specifically those with obesity (BMI > 30 kg/m2), in the development of IBD.
Ultra-Processed Foods Associated With Risk for Crohn Disease
Investigators analyzed the association between consumption of ultra-processed foods and risk for Crohn disease and ulcerative colitis.
Risankizumab Safe, Effective for Long-Term Treatment of Crohn Disease
Investigators conducted an open-label extension to evaluate the long-term safety and efficacy of risankizumab for the treatment of moderate to severe Crohn disease.
COVID-19 and IBD: Impact of Disease State and Biologics
In patients with IBD, management of immunosuppressive regimens, as well as safety and efficacy of vaccines, has raised many questions during the COVID-19 pandemic.
De-Escalation and Discontinuation of Biologics in IBD: What to Consider
Although the definition of remission varies, the goal of IBD treatment is to achieve and sustain remission.
Study Finds Link Between Depression, Anxiety Symptoms and Disease Activity in IBD
A team of investigators examined the association between disease activity in individuals with inflammatory bowel disease and the development of symptoms of depression and anxiety.
Clinical Remission Observed With Risankizumab in Crohn Disease Trials
Risankizumab is currently FDA-approved under the brand name Skyrizi for the treatment of moderate to severe plaque psoriasis.
- Loading...
Loading...
Next post in Gastroenterology Information Center
Loading... 
Loading...